However, another comprehensive analysis of U2AF1 mutations in 843 patients with myeloid neoplasms holds the view that U2AF1 mutants were only positively correlated with the occurrence of ASXL1 and KIT mutants in MDS/MPN patients, but not in MDS or AML patients [44]. This evidence concerns the gene U2AF1 and myeloproliferative neoplasm.